Drug intelligence / Profile preview

Magnolia kobus bark

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Magnolia kobus bark is derived from the Magnolia kobus tree, native to Japan and Korea. It has a long history of use in traditional Chinese and Japanese medicine. Bioactive constituents found in Magnolia bark, such as honokiol and magnolol, have demonstrated antidiabetic properties. These include improving hyperglycemia, ameliorating diabetic complications, and positively influencing lipid metabolism and oxidative stress. The bark also exhibits anti-inflammatory and antioxidant effects.

Other names: Kobus magnolia barkKobushi magnolia barkMokryeon bark

Targets

PTPN1 (Protein tyrosine phosphatase 1B)CNR1 (Cannabinoid receptor 1)INSR (Insulin receptor)ALOX5 (Arachidonate 5-lipoxygenase)TAK1 (Transforming growth factor beta–activated kinase 1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)

Beyond the preview

Go deeper on Magnolia kobus bark.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnolia kobus bark.

Explore the full profile